Matteo Santoni

Macerata, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 483 publications

Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

Machine learning-integrated explainable artificial intelligence for survival prediction in urothelial carcinoma with enfortumab vedotin: an exploratory real-world analysis.

Journal: Expert opinion on biological therapy

Published: August 29, 2026

Myositis in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-017 systematic review and meta-analysis.

Myositis in cancer patients receiving immune checkpoint inhibitors: the ARON-MOUSEION-017 systematic review and meta-analysis.

Journal: Expert opinion on drug safety

Published: August 13, 2026

Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006].

Corrigendum to "Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed" [Eur J Cancer 202, May 2024, 114006].

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 27, 2026

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Darolutamide versus abiraterone acetate-based triplets in patients with hormone-sensitive prostate cancer: real-world, head-to-head comparison from the ARON-3 study.

Journal: Minerva urology and nephrology

Published: June 23, 2026

Beyond prostate-specific antigen: ctDNA as an early compass for treatment adaptation in metastatic prostate cancer.

Beyond prostate-specific antigen: ctDNA as an early compass for treatment adaptation in metastatic prostate cancer.

Journal: Signal transduction and targeted therapy

Published: June 18, 2026

KIM-1 and beyond: emerging biomarkers for adjuvant immunotherapy in clear cell renal cell carcinoma.

KIM-1 and beyond: emerging biomarkers for adjuvant immunotherapy in clear cell renal cell carcinoma.

Journal: Expert review of molecular diagnostics

Published: June 09, 2026

Predictors of warfarin therapeutic dose in cancer patients: a preliminary comparative study using machine learning-integrated explainable artificial intelligence and Bayesian models.

Predictors of warfarin therapeutic dose in cancer patients: a preliminary comparative study using machine learning-integrated explainable artificial intelligence and Bayesian models.

Journal: Expert review of anticancer therapy

Published: May 29, 2026

International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma.

International multicenter experience of prognostic factors and treatment outcomes of metastatic non-clear cell renal cell carcinoma.

Journal: Tumori

Published: May 04, 2026

Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study.

Outcomes of first-line chemo-immunotherapy in advanced non-squamous NSCLC according to KRAS status: An Italian real-world study.

Journal: Tumori

Published: May 04, 2026

From Cystectomy to Conservation: Can Perioperative Enfortumab Vedotin Plus Pembrolizumab and Immuno-Radiotherapy Redefine the Standard of Care in Muscle-Invasive Bladder Cancer?

From Cystectomy to Conservation: Can Perioperative Enfortumab Vedotin Plus Pembrolizumab and Immuno-Radiotherapy Redefine the Standard of Care in Muscle-Invasive Bladder Cancer?

Journal: The Journal of urology

Published: April 28, 2026

Embarking on a new era in high-risk biochemical recurrent prostate cancer: redefining early systemic intervention.

Embarking on a new era in high-risk biochemical recurrent prostate cancer: redefining early systemic intervention.

Journal: Pharmacology & therapeutics

Published: April 28, 2026

Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).

Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study).

Journal: Minerva urology and nephrology

Published: April 23, 2026

Showing 1-12 of 483

Last Updated: 09/26/2026